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antibodies. Transplantation. 2009;87:415-418.Safety and Immunogenicity of the Live Attenuated
Varicella Vaccine Following T Replete or T Cell-Depleted
Related and Unrelated Allogeneic Hematopoietic Cell
Transplantation (alloHCT)
Joanne F. Chou, Nancy A. Kernan, Susan Prockop, Glenn Heller, Andromachi Scaradavou,
Rachel Kobos, Molly A. Knowles, Esperanza B. Papadopoulos, Anne Casson,
Catherine Copeland, Joanne Torok-Castanza, Nicole Zakak,
Julianne Ruggiero, Trudy N. SmallThere are limited studies assessing the live attenuated varicella vaccine following allogeneic hematopoietic cell
transplantation (alloHCT). Because of the morbidity of varicella acquired after childhood, we immunized and
retrospectively analyzed the safety and immunogenicity of this vaccine in 46 varicella zoster virus (VZV)
seronegative patients\20 years old at HCTwho achieved a CD4 cell count $200/mL, were off immuno-
suppression, and responded to $1 post-HCT vaccines. Two vaccinated patients lacking follow-up titers
were excluded from analysis. Stem cells were derived from an HLA-matched sibling (n5 18) or an alternative
(HLA mismatched related or unrelated) donor (n 5 26). Median time to vaccination was 4 years.
Sixty-four percent of patients seroconverted following 1 immunization. There was no significant difference
in response between recipients of amatched related or alternative donor graft (P5.2) or between those given
a T cell-depleted or T-replete alternative donor graft (P5 .27). Three of 44 patients developed a self-limited
varicella-like rash within 2.5 weeks of immunization. With a median follow-up of 29.1 (range: 6.9-167.1)
months, there were no subsequent cases of varicella-like rashes. No patient developed shingles. This studyenter, New York City, New York.
t of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-
e-mail: smallt@mskcc.org).
Biol Blood Marrow Transplant 17:1698-1720, 2011 1709Varicella Vaccine Post-allogeneic HCTsuggests that this vaccine is safe and immunogenic when given according to preset clinical and immunologic
milestones, warranting larger prospective studies in patients $24 months following HCT as outlined in
current post-HCT vaccine guidelines.
Biol Blood Marrow Transplant 17: 1708-1713 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: Varicella, Allogeneic, ImmunizationINTRODUCTION
Although varicella in childhood is generally a mild
disease, immunocompetent individuals who develop
chickenpox later in life develop a more serious infection,
associated with an increased risk of visceral disease and
need for hospitalization [1,2]. In individuals .20 years
of age, fatal varicella is 13 times higher than that
observed in children [2]. Studies have documented the
safety and efficacy of the live attenuated varicella vaccine
in healthy children [3] and patients with a history of
impaired cellular or humoral immunity [4,5], such
as children with acute lymphoblastic leukemia on
maintenance therapy [6], pediatric solid organ transplant
recipients on chronic immunosuppressive therapy [7,8],
and treated children with HIV [9-11]. In view of this,
our center has chosen to vaccinate varicella zoster virus
(VZV) seronegative children and adolescents after
allogeneic hematopoietic cell transplantation (alloHCT)
upon acquisition of preset immune milestones.
Although both the 2005 European Group for Blood and
Marrow Transplantation (EBMT) [12] and the 2009
[13] Center for International Blood and Marrow Trans-
plant Research (CIBMTR) vaccine guidelines permit the
use of a live attenuated varicella vaccine in select patient
groups, there is minimal data on the immunogenicity
of this vaccine post-HCT [14-16], particularly in
recipients of cord blood, unrelated HCT derived from
any source, and children transplanted for primary
immunodeficiency disease. In view of this, this
retrospective study analyzed the safety and
immunogenicity of this vaccine in allogeneic
transplantation recipients. The effect of age at
transplantation and vaccination, diagnosis, time from
HCT to vaccination, donor type, and stem cell source,
history of graft-versus-host disease (GVHD), and/or the
use of T cell depletion on vaccine responses was assessed.PATIENTS, MATERIALS, AND METHODS
A waiver of authorization to conduct this study was
approved by the Memorial Sloan-Kettering Cancer
Center (MSKCC) institutional review board. Themed-
ical records of all patients\20 years old at HCT who
were disease-free for .10 months following an
allogeneic transplantation performed from 1/1/1995
through 12/1/08were reviewed for receipt of the live at-
tenuated varicella vaccine. At this center, VZV seroneg-
ative patients were eligible for vaccination if they were$24 months following transplantation, were off all
immunosuppressive therapy, and had no evidence of on-
going chronic GVHD (cGVHD). To increase vaccine
safety, patients were required to have a circulating
CD4cell count (.200 cells/mL), aTcell proliferative re-
sponse against Phytohemagglutinin (PHA) within the
lower limit of normal, and a specific antibody response
to $1 vaccines administered post-HCT. Four patients
were immunized by their local physicians \2 years
post-HCT despite our recommendations to delay im-
munization until $24 months. Dates of vaccination
and pre- and postvaccine titers were obtained from
a prospectively maintained database and confirmed by
retrospective chart review. Pre- and posttiters were
available on 44 patients; 2 vaccinated patients without
follow-up titerswere excluded fromanalysis. All patients
were evaluated at MSKCC before and after completing
vaccinations, including assessment of acute (aGVHD)
and cGVHD using established criteria [17,18]. Ninety
percent of patients were vaccinated at MSKCC.
Immunologic Evaluations
Antibody testing
Varicella antibody was measured in the Clinical
Microbiology Laboratory of MSKCC using a 2-step
enzyme immunoassay sandwich method with a final
fluorescent detection (BIOMERIEUX, Durham, NC).
The result is indicated by test value calculated by the
computer basedon the ratio from the relative fluorescent
value of the sample to that of the standards that are run
for each test. A test value.0.9 is considered positive.
Four-color immunofluorescence and T cell
proliferative responses
Circulating lymphoid populations were analyzed by
4-color immunofluorescencewithin 3months of initiat-
ing vaccination using methods as previously described
[19]. In vitro T cell proliferative responses to phytohe-
magglutinin and varicella virus were performed as fol-
lows: 50,000 isolated peripheral blood mononuclear
cells were resuspended in RPMI, supplemented with
10% pooled human serum, penicillin/streptomycin,
and L-glutamine, and plated in round-bottom micro-
titer wells in a volume of 175 mL/well. Cells were stim-
ulated with phytohemagglutinin (PHA-P, DIFCO,
Sparks, MD) at optimal final concentrations of
42.9, 21.4, and 10.7 mg/mL of culture and Varicella
Zoster CF antigen (1:10, 1:20, 1:40, 1:80 dilution)
Table 1. Patient and Donor Characteristics
N 5 44











Time (median, range) from HCT to vaccine 4.0 (0.92-14.04) years
Age (range) at vaccination 8.9 (2.48-31.3) years
Transplant type
Unmodified (n 5 31)
HLA-Matched sibling 17
Unrelated Adult donor 8
Unrelated cord blood (single/double unit) 5 (1/4)
T cell depleted (n 5 13)
HLA Matched sibling 1
HLA Mismatched Related 6
Unrelated 7
HCT indicates hematopoietic cell transplantation; SCID, severe com-
bined immunodeficiency.
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labeled with 1.0 mCi/well 3H-thymidine for the last 24
hours of the 120-hour incubation for PHA and 168
hours for varicella, harvested onto glass-fiber filter pa-
per, and counted in a liquid scintillation counter. The
absolute proliferative responsewas calculated as theme-
dian counts per minute (cpm) of triplicate wells minus
the unstimulated medium control. Each day, all assays
performedonpatientswere run inparallelwith a normal
control and compared with values derived from 60 nor-
mal controls evaluated every 2 years.
Statistical Analysis
The Fisher exact test and the Wilcoxon rank sum
test was used to examine covariate differences between
responders and nonresponders. The SAS statistical
package (version 9.2) (SAS Institute Inc., Cary, NC)
was used to generate the test statistics. Only P values
\.05 were considered statistically significant.
Patient and Transplant Characteristics
Patient and donor characteristics are shown in
Table 1. The majority of patients were transplanted
for a hematologicmalignancy (57%) or primary immu-
nodeficiency disease (23%).The stem cell donorwas an
HLA-A, B, DRb1 identical sibling, a haplo-identical
family member, or an unrelated donor in 41%, 14%,
and 45% of cases, respectively. Seventy percent of
patients received an unmodified HCT. Of the remain-
ing 13 patients, 8 received a bone marrow transplant
(BMT) T cell depleted by either soybean lectin agglu-
tination followed by rosetting with sheep erythrocytes
(n 5 6) [20] or treatment with the T10B9 monoclonal
antibody plus complement (n5 2) [21], and 5 receiveda peripheral blood stem cell graft T cell depleted by
CD34 positive selection followed by rosetting with
sheep erythrocytes [22]. Eight-nine percent of patients
received myeloablative cytoreduction that contained
either hyperfractionated total body irradiation (TBI)
(n5 15) or.8mg/kg busulfan (n5 24). Three patients
received nonmyeloablative conditioning (melphalan,
fludarabine, anti-CD52 [n 5 2] or cyclophosphamide,
and antithymocyte globulin [ATG; n 5 1]). Two
patients with severe combined immunodeficiency dis-
ease (SCID) received an HLA matched sibling BMT
without prior cytoreduction. Three patients received
posttransplantation rituximab at 25, 49, and 50months
before vaccination for the treatment of a severe auto-
immune hemolytic anemia following an unmodified,
unrelated BMT (n 5 1) or to prevent an Epstein-Barr
virus lymphoproliferative disorder following a T cell-
depleted unrelated peripheral blood stem cell trans-
plantation (n 5 2). Six patients had a history of grade
II-III aGVHD, and 3 patients developed cGVHD,
which had resolved in all patients before vaccination.RESULTS
Before receipt of the live attenuated varicella
vaccine, all patients were VZV seronegative, and 42
of 44 patients lacked a T cell proliferative response
against varicella antigen. The median age at vaccina-
tion was 9 years. The median time from transplanta-
tion to vaccination was 4 years, with a range of
0.92-14.04 years. The wide range between HCT and
immunization was because of the time it took patients
to discontinue immunosuppression, reach immuno-
logic milestones, and/or physician comfort adminis-
tering the live attenuated varicella vaccine. There
was no significant difference in time to vaccine in
recipients of T cell-depleted or T-replete transplanta-
tion. The median time to first live attenuated varicella
vaccine was 3.9 (range: 0.92-14.04) years following
a T cell-depleted HCT and 4.1 (range: 1.67-9.13)
years postunmodified HCT, P 5 .64.B and T Cell-Specific Responses
Themedian time tomeasure antibody levels follow-
ing the initial vaccine was 108 days (range: 29-395 days).
Overall, 64%(28of44) ofpatients seroconverted follow-
ing 1 vaccine. There was no significant difference in the
proportion of responders in patients evaluated \ or
.108 days postimmunization (14 of 23 vs 15 of 22). Re-
sponse was observed in 50% (7 of 14), 68% (13 of 19),
and 73% (8 of 11) of patients immunized between 0.92
and 3, 3 and 5, and .5 years post-HCT. There was no
significant difference in B cell response on the basis of
age atHCT, age at vaccination, patient diagnosis, or his-
tory of resolved aGVHD or cGVHD (data not shown).
Eight of 10 patients transplanted for a primary
Figure 1. Antibody response following second live attenuated varicella
vaccine in patients who did not seroconvert following their initial vac-
cine (n 5 14). This figure demonstrates VZV titers in 14 patients given
a second varicella vaccine following lack of response to initial immuniza-
tion. The figure demonstrates VZV titer obtained before the vaccine
(pretiter), following the first immunization, and again following the sec-
ond immunization. Response is shown in 8 recipients of an HLA-
matched sibling HCT (left) and 6 recipients of an unrelated HCT (right).
Horizontal line drawn at value of 0.9, above which is positive.
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tenuated varicella vaccine administered at a median
(range) of 3.3 (1.6-4.9) years post-HCT. There was no
significant difference in response in recipients of an
HLAmatched related compared with an alternative do-
norHCT (9 of 18 vs 19 of 26), respectively (P5 .2). Ten
of 12 and 9 of 14 recipients of a T cell-depleted orT-re-
plete alternative donor HCT seroconverted after 1 live
attenuated varicella vaccine, respectively (P 5 .27).
Three of 5 patientswho received a cord blood transplant
seroconverted following their first vaccine administered
at a median (range) of 3.76 (2.76-5.89) months post-
HCT.
Fourteen patients who did not respond to the first
live attenuated varicella vaccine received a second im-
munization at a median of 7.2 (range: 2.7-14.6) months
following the primary live attenuated varicella vaccine.
Seven of 8 recipients of an unmodified HLA matched
sibling HCT and 3 of 6 recipients of an unrelated
HCT (P 5 .16) seroconverted following the second
vaccine (Figure 1).
Following the initial live attenuated varicella vac-
cine, in vitro T cell proliferative response against
VZV was assessed in 17 patients who seroconverted
and 14 patients who did not. Of the 17 patients who
mounted a B cell response, 13 developed a VZV spe-
cific T cell proliferative response. Despite failure to
seroconvert, 7 of 14 patients developed a specific in
vitro T cell response against varicella.
Safety
Nopatient suffereda serious adverse reaction attrib-
utable to vaccination. Three unrelated transplant recip-
ients (cord blood, n 5 1; unmodified PBSCT, n 5 1;
T10B9 1 complement TCD BMT, n 5 1), developed
amild (\25 vesicles) disseminated rashwithin 2.5weeks
of vaccination. The rash resolved in all 3 patients within7 days of onset without treatment. Currently, 43 of 44
patients are alive, disease-free with a median (range)
follow-up of 29.1 (6.9-167.1) months postimmuniza-
tion. There have been no cases of primary varicella or
a varicella-like rash .2.5 weeks postvaccination nor
any cases of shingles. No patient has required acyclovir,
gammaglobulin, or hyperimmune zoster immune glob-
ulin since vaccination.DISCUSSION
Reactivation of wild-type varicella is known to cause
significant morbidity and occasionallymortality follow-
ing an alloHCT [23,24]. The risk of shingles in younger
patients whose VZV immunity was acquired through
vaccination rather thanwild-typedisease is currentlyun-
known. In addition, patients immunized in early child-
hood who undergo HCT later in life may be at an
increased risk of varicella because of the known loss of
vaccine immunity even in healthy recipients of a single
live attenuated varicella vaccine [25]. In a 10-year study
by Chaves et al. [26] of 11,356 healthy vaccinated
subjects, 1080 developed breakthrough varicella. The
annual rate of breakthrough disease increased signifi-
cantly with time following immunization, with 1.6 com-
pared with 58.2 cases per 1000 person-years occurring
within 1 year and 9 years post-live attenuated varicella
vaccine, respectively. The risk of breakthough disease
was highest in children 8 to 12 years of age who were
5 or more years following immunization.
Although both the 2005 EBMT [12] and 2009
CIBMTR [13] guidelines permit the use of the live
varicella vaccine in select patient groups starting at
24 months post-HCT, only 2 published studies
have assessed safety and/or response in alloHCT
recipients. Sauerbrei and colleagues [14] vaccinated 15
pediatric patients, 8 of whom received an alloHCT. Pa-
tients were vaccinated at a median of 18 (range: 12-23)
months post-HCT. Immunologic criteria for vaccina-
tion included a circulating lymphocyte count of
.1000 cells/mL, serum IgG .500 mg/dL, and
a positive skin test to a recall antigen. Of the 4 VZV
seronegative allogeneic patients immunized, 3 of 4
seroconverted at 6 weeks postimmunization. Kussmaul
and colleagues [15] evaluated the safety of the live atten-
uatedvaricella vaccine in18autologous and50alloHCT
recipients, 25 of whom were evaluable for response. El-
igibility for vaccination included a circulating CD4
count of $200 cells/mL, a PHA response at least 50%
of the lower limit of normal, a humoral response to the
inactivated polio vaccine, and specific T and B cell re-
sponse to tetanus toxoid. The median time to the first
live attenuated varicella vaccine was 32 months post-
HCT (range: 16-144 months). There were no serious
vaccine-related events. Although the study byKussmaul
et al. [16] did not stipulate the proportion of responders
who received an autologous versus an alloHCT, of the
1712 Biol Blood Marrow Transplant 17:1698-1720, 2011J. F. Chou et al.25 patients clearly evaluable for response, seroconver-
sion occurred in 40%, 8%, and 4% of patients after 1,
2, or 3 vaccines, respectively.
Our study, although retrospective, represents the
largest series analyzing the response of VZV seroneg-
ative patients following HCT vaccinated with live
attenuated varicella vaccine. Although an ELISA was
used to assess response, the seroconversion rate fol-
lowing the live attenuated varicella vaccine in our study
is not markedly different than the 74% conversion rate
observed in healthy children when measured by the
highly sensitive fluorescent antibody to membrane
antigen (FAMA) [27]. The latter assay requires viral
propagation in tissue culture, is not commercially
available, and requires considerable operator expertise.
In view of this, several studies [7-9,14,16], including
ours, have used an ELISA-based method to measure
response to the live attenuated varicella vaccine.
The risk of shingles following the live attenuated
varicella vaccine has been 1 of the main concerns
surrounding immunization of children against chicken-
pox, particularly those with a history of or ongoing
immunodeficiency [27,28]. This risk has been
evaluated in children with a history of leukemia [29], pe-
diatric recipients of solid organ transplants [7,8], and
HIV infected children on retroviral therapy [9-11].
Studies in these populations have not shown an
increased risk of VZV. In 1989, Lawrence et al. [28]
compared the risk of shingles in childrenwith acute lym-
phoblastic leukemia (ALL) in remission who were im-
munized versus those with a history of natural
infection.Of the 346 immunized children, the incidence
of zosterwas 0.552 cases/100person-years. In a subset of
82 matched pairs, there was no significant difference in
the incidenceof shingles inpatientswhowerevaccinated
(1.23 cases per 100 person-years) compared with 3.11
cases in children with a history of varicella, respectively
(P 5 NS). In 2009, Civen and colleagues [29] demon-
strated that immunized children\10 years old had a 4
to 12 times lower risk of developing shingles than chil-
dren with a history of chickenpox.
Because of breakthrough cases of varicella in recip-
ients of a single vaccine, the Advisory Committee on
Immunization Practices (ACIP) currently recom-
mends a 2-dose schedule in healthy children at 12 to
15 months and 4 to 6 years, a second dose in children,
adolescents, and adults previously given only 1 vaccine,
routine immunization of all healthy VZV seronegative
individuals 13 years of age or older, and immunization
of HIV-infected children and adults with circulating
CD41 T lymphocyte counts .200 cells/mL [3]. Our
study supports the use of the live attenuated varicella
vaccine in VZV seronegative patients. The dichotomy
of T and B cell responses in some of our patients
(ie, seroconversion in the absence of concurrent
T cell response) suggest that kinetics of recovery of
lymphoid populations required for a full responsemay differ from patient to patient. Larger prospective
trials assessing the safety, immunogenicity, protection
against chickenpox, and subsequent risk of shingles
following the live attenuated varicella vaccine in
this population are needed. Ideally, trials should be
designed to identify biological markers that might
allow earlier revaccination of patients with the requi-
site T and B cell populations and prevent premature
vaccination and/or risk in patients unable to respond.ACKNOWLEDGMENTS
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2009;28:954-959.The Incidence of Veno-Occlusive Disease Following
Allogeneic Hematopoietic Stem Cell Transplantation
Has Diminished and the Outcome Improved over the
Last Decade
Enric Carreras, Marina Dıaz-Beya, Laura Rosi~nol, Carmen Martınez,
Francesc Fernandez-Aviles, Montserrat RoviraThe evolution of the incidence, morbidity, and mortality of veno-occlusive disease (VOD) was analyzed in
845 allogeneic hematopoietic stem cell transplantations (allo-HSCTs) performed over 24 years. A total of
117 patients and 73 patients developed VOD following the Seattle and the Baltimore diagnostic criteria,
respectively (cumulative incidence 13.8% and 8.8%). The cumulative incidence was significantly higher in
the period 1985 to 1996 than in 1997 to 2008 (11.5% vs 6.5%; P 5 .01). This decline was because of the
low incidence of VOD among reduced-intensity conditioning-HSCT (RIC-HSCT) (2.1%) and the reduction
among those receiving myeloablative-HSCT from unrelated donors (32.7% vs 10.5%, P5 .001). A total of 35
patients had severe VOD (26 with multiorgan failure [MOF]), and 20 died by VOD (cumulative mortality rate’Investigacions Biomediques Agustı Pi i Sunyer (IDIBAPS), Univer-
matologyDepartment, Hospital Clınic, Institut d’Investigacions Bio-
larroel 170, 08036 Barcelona, Spain (e-mail: carreras@clinic.ub.es).
